329 filings
Page 3 of 17
8-K
cayar i2ysbsnl9cg1
26 Jun 20
Entry into a Material Definitive Agreement
4:30pm
8-K
3fe6z779x5bw
11 May 20
NASH-RX Clinical Trial Protocol Filed with FDA; First Patient Currently Expected to be Enrolled in Second Quarter 2020
7:48am
8-K
m50ldr
30 Apr 20
The first patient currently expected to be enrolled in the second quarter of 2020
8:55am
8-K
ulp0 7mi56
17 Mar 20
Entry into a Material Definitive Agreement
8:01am
8-K
d9q19v6
16 Mar 20
Galectin Therapeutics Reports Fiscal 2019 Financial Results
7:57am
8-K
7z9seuxg3y0y1zp1
20 Feb 20
Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive
7:55am
8-K
edmfug8dwkm2k
6 Dec 19
Submission of Matters to a Vote of Security Holders
9:01am
8-K
shdejqkdr2tg6ku2i
4 Dec 19
Regulation FD Disclosure
9:26am
8-K
5r4y dqy6j
26 Nov 19
Other Events
7:55am
8-K
6hoic
12 Nov 19
Galectin Therapeutics Reports Q3 2019 Financial Results
7:54am
8-K
i9io4ny7uq 10rwl
27 Sep 19
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
8:30am
8-K
lx2yv88739xvzw
17 Sep 19
Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin(GR-MD-02) in Cancer Immunotherapy
7:50am
8-K
t7x53q05c7rhvb0anxh3
9 Aug 19
Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update
7:59am
8-K
jqndj1o1
5 Aug 19
Other Events
8:00am
8-K
ehyjihi6x3 zyj
28 May 19
Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million From Warrant Exercise
8:55am
8-K
2aig 2qkvle
10 May 19
Other Events
7:59am
8-K
j1l q00nm1h9tqb
10 May 19
Galectin Therapeutics Reports Q1 2019 Financial Results
7:56am
8-K
te6s870xvoz0iwjr91
15 Apr 19
And Expiration Date for Rights Offering and Effectiveness of Its
7:55am
8-K
dyp57nm
21 Mar 19
Regulation FD Disclosure
5:00pm
8-K
j9im1vt urpi7wwvh
6 Mar 19
Other Events
7:58am